세계의 IND(Investigational New Drug) CDMO 시장 : 시장 규모, 점유율 및 동향 분석(서비스별, 최종 용도별, 지역별), 부문별 예측(2025-2033년)

Investigational New Drug CDMO Market Summary

The global investigational new drug CDMO market size was estimated at USD 5.21 billion in 2024 and is projected to reach USD 10.40 billion by 2033, growing at a CAGR of 8.66% from 2025 to 2033. The investigational new drug (IND) CDMO market has been driven by rising outsourcing demand from pharmaceutical & biotechnology companies, increasing pipeline complexity, and growing need for cost efficiency among companies.

Besides, increased emphasis on accelerating time-to-market, while early-phase development risks have been managed through partnerships with specialized CDMOs. In addition, growing therapeutic focus on oncology, rare diseases, and advanced biologics has further fueled IND new drug CDMO services.

Moreover, growing technological advancements have been adopted to strengthen CDMO service offerings across the IND space. Besides, artificial intelligence, advanced analytical platforms, organoid-based preclinical models, and digital regulatory systems have been integrated into operations to enable faster, data-rich development. Single-use bioprocessing and continuous manufacturing have provided flexibility in early-stage production, ensuring scalability and efficiency. Furthermore, investments have been directed toward expanding laboratory infrastructure, specialized bioassay capabilities, and digital quality systems to capture higher-value IND projects. In addition, strategic capital allocated to mergers, acquisitions, and alliances are enabling CDMOs to broaden service portfolios and expand global footprints. Private equity and venture capital activity has continued to support niche CDMOs, particularly those focused on biologics and cell and gene therapy.

Furthermore, the regulatory landscape has remained a critical determinant of IND CDMO performance. Increased scrutiny from the U.S. FDA, EMA, and other regional agencies has been observed, requiring adherence to evolving quality standards. Data integrity, transparency in early toxicology and bioanalytical submissions, and compliance with good laboratory and manufacturing practices have been emphasized, creating challenges and opportunities for differentiation.

Overall, the IND CDMO market has been characterized by rising demand, rapid technological adoption, and strategic expansion. In addition, market participants have been operating under competitive pressures to provide integrated, end-to-end solutions while balancing cost efficiency and compliance. This growth has been supported by globalized operations, diversified portfolios, and a focus on collaborative innovation, positioning CDMOs as indispensable partners in the early stages of drug development.

Global Investigational New Drug CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global investigational new drug CDMO market report based on service, end use, and region.

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
  • Small Molecule
  • Bioanalysis and DMPK Studies
  • Toxicology Testing
  • Pathology and Safety Pharmacology Studies
  • Drug Substance Development
  • Synthetic Route Development
  • Process Development
  • Form Selection Crystallization Process Development
  • Scale-up of Drug Substance
  • Formulation Development
  • Pre Formulation
  • Preclinical Formulation Selection
  • First In Man Formulation/ Process Development
  • Analytical & Quality Services
  • Analytical Method Development / Validation
  • Release Testing of Drug Substance and Drug Product
  • Formal Stability of Drug Substance and Drug Product
  • Process Optimization
  • Work Up Purification Steps
  • Telescoping & Process Refining
  • Initial Optimization
  • Large Molecule
  • Cell Line Development
  • Process Development
  • Upstream
  • Microbial
  • Mammalian
  • Others
  • Downstream
  • MABs
  • Recombinant Proteins
  • Others
• Contract Manufacturing
  • Small Molecule
  • Oral Solids
  • Semi-Solids
  • Liquids & Injectables
  • Others
  • Large Molecule
  • MABs
  • Recombinant Proteins
  • Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical Companies
• Biotech Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Investigational New Drug CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing outsourcing services by pharmaceutical companies
    • 3.2.1.2. Rising investment in R&D
    • 3.2.1.3. Growing pharmaceutical industry
    • 3.2.1.4. Stringent regulatory requirements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance issues while outsourcing
    • 3.2.2.2. Changing scenario in developing countries
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Investigational New Drug CDMO Market: Service Estimates & Trend Analysis

• 4.1. Investigational New Drug CDMO Market, By Service: Segment Dashboard
• 4.2. Investigational New Drug CDMO Market, By Service: Movement Analysis
• 4.3. Investigational New Drug CDMO Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 4.4. Contract Development
  • 4.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Small Molecule
    • 4.4.2.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.2. Bioanalysis and DMPK Studies
      • 4.4.2.2.1. Bioanalysis and DMPK Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.3. Toxicology Testing
      • 4.4.2.3.1. Toxicology Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.4. Pathology and Safety Pharmacology Studies
      • 4.4.2.4.1. Pathology and Safety Pharmacology Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.5. Drug Substance Development
      • 4.4.2.5.1. Drug Substance Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.5.2. Synthetic Route Development
        • 4.4.2.5.2.1. Synthetic Route Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.5.3. Process Development
        • 4.4.2.5.3.1. Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.5.4. Form Selection Crystallization Process Development
        • 4.4.2.5.4.1. Form Selection Crystallization Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.5.5. Scale-up of Drug Substance
        • 4.4.2.5.5.1. Scale-up of Drug Substance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.6. Formulation Development
      • 4.4.2.6.1. Formulation Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.6.2. Pre Formulation
        • 4.4.2.6.2.1. Pre Formulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.6.3. Preclinical Formulation Selection
        • 4.4.2.6.3.1. Preclinical Formulation Selection Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.6.4. First In Man Formulation/ Process Development
        • 4.4.2.6.4.1. First In Man Formulation/ Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.7. Analytical & Quality Services
      • 4.4.2.7.1. Analytical & Quality Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.7.2. Analytical Method Development / Validation
        • 4.4.2.7.2.1. Analytical Method Development / Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.7.3. Release Testing of Drug Substance and Drug Product
        • 4.4.2.7.3.1. Release Testing of Drug Substance and Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.7.4. Formal Stability of Drug Substance and Drug Product
        • 4.4.2.7.4.1. Formal Stability of Drug Substance and Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.8. Process Optimization
      • 4.4.2.8.1. Process Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.8.2. Work Up Purification Steps
        • 4.4.2.8.2.1. Work Up Purification Steps Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.8.3. Telescoping & Process Refining
        • 4.4.2.8.3.1. Telescoping & Process Refining Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.8.4. Initial Optimization
        • 4.4.2.8.4.1. Initial Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Large Molecule
    • 4.4.3.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.2. Cell Line Development
      • 4.4.3.2.1. Cell Line Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.3. Process Development
      • 4.4.3.3.1. Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.3.2. Upstream
        • 4.4.3.3.2.1. Upstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.3.3.2.2. Microbial
          • 4.4.3.3.2.2.1. Microbial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.3.3.2.3. Mammalian
          • 4.4.3.3.2.3.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.3.3.2.4. Others
          • 4.4.3.3.2.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.3.3. Downstream
        • 4.4.3.3.3.1. Downstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.3.3.3.2. MABs
          • 4.4.3.3.3.2.1. MABs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.3.3.3.3. Recombinant Proteins
          • 4.4.3.3.3.3.1. Recombinant Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.4.3.3.3.4. Others
          • 4.4.3.3.3.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Contract Manufacturing
  • 4.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Small Molecule
    • 4.5.2.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.2. Oral Solids
      • 4.5.2.2.1. Oral Solids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.3. Semi-Solids
      • 4.5.2.3.1. Semi-Solids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.4. Liquids & Injectables
      • 4.5.2.4.1. Liquids & Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2.5. Others
      • 4.5.2.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Large Molecule
    • 4.5.3.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.2. MABs
      • 4.5.3.2.1. MABs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.3. Recombinant Proteins
      • 4.5.3.3.1. Recombinant Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.4. Others
      • 4.5.3.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Investigational New Drug CDMO Market: by End Use Estimates & Trend Analysis

• 5.1. Investigational New Drug CDMO Market, by End Use: Segment Dashboard
• 5.2. Investigational New Drug CDMO Market, by End Use: Movement Analysis
• 5.3. Investigational New Drug CDMO Market Estimates & Forecasts, by End Use, 2021 - 2033 (USD Million)
• 5.4. Pharmaceutical Companies
  • 5.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Biotech Companies
  • 5.5.1. Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Investigational New Drug CDMO Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2033
• 6.3. North America
  • 6.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. U.S
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Competitive Scenario
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Competitive Scenario
    • 6.4.8.3. Regulatory Framework
    • 6.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Competitive Scenario
    • 6.4.9.3. Regulatory Framework
    • 6.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. South Korea
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. Saudi Arabia
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.6. Qatar
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.7. Oman
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Key Participant Categorization
  • 7.1.1. Market Leaders
  • 7.1.2. Emerging Players
• 7.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 7.3. Company Profiles
  • 7.3.1. Catalent, Inc.
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Service Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. Lonza
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Service Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Recipharm AB
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Service Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. Siegfried Holding AG
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Service Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Patheon Inc.
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Service Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. Covance
    • 7.3.6.1. Company Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Service Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. IQVIA Holdings Inc.
    • 7.3.7.1. Company Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Service Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Cambrex Corporation
    • 7.3.8.1. Company Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Service Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Charles River Laboratories International, Inc.
    • 7.3.9.1. Company Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Service Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Syneos Health
    • 7.3.10.1. Company Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Service Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. Syngene International
    • 7.3.11.1. Company Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Service Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. Jubilant Pharmova
    • 7.3.12.1. Company Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Service Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Piramal Pharma Solutions
    • 7.3.13.1. Company Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Service Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Dr. Reddy's CPS
    • 7.3.14.1. Company Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Service Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. Dishman Carbogen Amcis
    • 7.3.15.1. Company Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Service Benchmarking
    • 7.3.15.4. Strategic Initiatives
  • 7.3.16. Biocon Biologics
    • 7.3.16.1. Company Overview
    • 7.3.16.2. Financial Performance
    • 7.3.16.3. Service Benchmarking
    • 7.3.16.4. Strategic Initiatives
  • 7.3.17. Laurus Labs
    • 7.3.17.1. Company Overview
    • 7.3.17.2. Financial Performance
    • 7.3.17.3. Service Benchmarking
    • 7.3.17.4. Strategic Initiatives